氯酯醒治疗血管性痴呆的有效性和安全性研究

目的评价氯酯醒胶囊治疗血管性痴呆的有效性及安全性。方法选择56例血管性痴呆患者，用氯酯醒进行12周的治疗（0．2Tid），治疗前后用简易精神状态量表（MMSE）、临床痴呆量表（CDR）及日常生活自理量表（ADL）评分，判定疗效。结果氯酯醒治疗12用后与治疗前相比，MMSE、CDR及ADL分数分别改善4．69、0．82和4．71分，差异具有显著性意义。在用药初期3例出现血压轻度升高，2例出现头晕、头痛，1例出现胃部不适、恶心，2例出现兴奋或失眠等症状。结论氯酯醒能有效治疗血管性痴呆患者，对患者的认知功能、痴呆程度和日常生活自理能力均有改善．且安全性较好。

Safety and efficacy of Meclofenoxate in treatment of patients with vascular dementia

[Objective] To assess the efficacy and safety of Meclofenoxate in treatment of vascular dementia (VaD). [Methods] 56 patients with VaD were followed up with self-matched study for 12 weeks in department of Neurology and received MMSE, CDR and ADL test. [Results] The results of self-matched trial showed remarkable improvement in MMSE, CDR and ADL by 4.69, 0.82, 4.71 points respectively (P <0.01, 0.05, 0.05) respectively after treatment with Meclofenoxate (0.2 tid) for 12 weeks. Eight of 56 patients showed mild side effects, such as dizziness, headache and nausea. [Conclusions] Meclofenoxate is effective in treating patients with VaD. It can improve cognition and ability of daily life. Meclofenoxate was well tolerated and safe.